Trillium Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Trillium Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.9M	Sell	60,105 -39,657	-40%	-$17.6M	0.92%	28
2026 Q1	$28.1M	Buy	99,762 +37,069	+59%	+$17.3M	0.93%	27
2025 Q4	$28.6M	Sell	62,693 -5,692	-8%	-$2.45M	0.87%	33
2025 Q3	$26.8M	Buy	68,385 +6,911	+11%	+$2.89M	0.71%	43
2025 Q2	$27.4M	Buy	61,474 +5,658	+10%	+$2.61M	0.74%	40
2025 Q1	$27.1M	Buy	55,816 +38,854	+229%	+$18.1M	0.78%	38
2024 Q4	$6.83M	Sell	16,962 -1,122	-6%	-$520K	0.18%	123
2024 Q3	$8.41M	Buy	18,084 +505	+3%	+$243K	0.21%	109
2024 Q2	$8.24M	Buy	+17,579	New	+$7.63M	0.21%	108

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Trillium Asset Management's VRTX Position: Q2 2026 in Review

Trillium Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 40% in Q2 2026, selling an estimated $17.6M and leaving 60,105 shares worth $29.9M. The position accounts for 0.92% of the portfolio, ranked #28.

Trillium Asset Management first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Trillium Asset Management held 60,105 shares of Vertex Pharmaceuticals worth $29.9M as of Q2 2026.
Trillium Asset Management sold 39,657 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.6M.
Vertex Pharmaceuticals made up 0.92% of Trillium Asset Management's portfolio in Q2 2026, its #28 holding.
Trillium Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trillium Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.